Tagrisso (osimertinib): Insurance Coverage and Denials
A plain-language guide to EGFR tyrosine kinase inhibitor coverage, why insurers deny it, and where to get cancer-specific help.
Tagrisso is an oral targeted therapy classified as an EGFR tyrosine kinase inhibitor. It blocks signaling from specific mutated forms of the EGFR protein that drive tumor growth in some lung cancers. The FDA has approved Tagrisso for non-small cell lung cancer with certain EGFR mutations, including exon 19 deletions and exon 21 L858R mutations, across settings that range from after surgery to locally advanced and metastatic disease, and for EGFR T790M-positive disease after prior EGFR therapy.
Insurers commonly require prior authorization and almost always demand documentation of the specific EGFR mutation from molecular testing, along with confirmation of disease stage and line of therapy. Denials and delays frequently stem from missing biomarker test results or specialty-pharmacy dispensing requirements.
If your plan denies coverage, you generally have the right to an internal appeal followed by an independent external review under federal rules such as 45 CFR 147.136. For specialized cancer help, contact the PAN Foundation, Patient Advocate Foundation, Triage Cancer, CancerCare, or AstraZeneca's Tagrisso copay and patient-assistance programs.
Where to get cancer-specific help
A note on scope. Apellica focuses on appeals for non-oncology insurance denials and does not handle cancer-related appeal cases. Cancer coverage involves complex, fast-moving clinical and financial questions, and patients are best served by organizations built specifically for oncology. If you are facing a cancer drug denial, please reach out to the specialized groups listed on this page, including the PAN Foundation, the Patient Advocate Foundation, Triage Cancer, and CancerCare, along with the manufacturer's own copay or patient-assistance program. They offer free, expert, cancer-focused support, and they can help you understand your options and protect your access to treatment. ---
- PAN Foundation Copay and financial assistance funds for specific diagnoses.
- Patient Advocate Foundation Case managers who help with insurance denials and appeals for serious illness.
- Triage Cancer Free education and resources on cancer-related insurance and appeals.
- CancerCare Professional support services and financial assistance.
Oncology clinics and manufacturers
Apellica partners with infusion centers, oncology practices, and pharmaceutical manufacturers on denial recovery and patient access at scale. If you are exploring a partnership, we would like to talk.
Partner with usFrequently asked questions
- Why do insurers deny Tagrisso?
- EGFR biomarker test documentation; Line-of-therapy requirements; Prior authorization criteria.
- Can I appeal a Tagrisso denial?
- Yes. You generally have the right to an internal appeal and then an independent external review under federal rules such as 45 CFR 147.136. For cancer-specific help, the organizations listed on this page specialize in oncology coverage.